Abstract:Objective The malignant progression from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is common and has detrimental effect on patients. We aimed to elucidate the underlying mechanisms of the malignant progression from an immunological perspective and establish a reliable signature for prognostic prediction and immunotherapeutic strategies. Methods The Cell Type Identification by Estimating Relative Subsets of RNA Transcripts algorithm was applied to the GSE32894 data set to identify the different tumor-infiltrating immune cells involved in NMIBC and MIBC. Using weighted gene correlation network analysis, survival analysis and least absolute shrinkage and selection operator Cox analysis, we established an immune prognostic signature (IPS) based on 14 overall survival-associated immune genes in The Cancer Genome Atlas (TCGA). Functional enrichment analyses and nomogram were performed to explore the potential effects and prognostic performance of the IPS. Furthermore, the RNA-sequence data from our center were used to validate the expression levels of the selected immune genes in BLCA samples. Results Diverse proportions of macrophage subtypes were observed between NMIBC and MIBC. Patients with high risk scores had a worse prognosis than patients with low risk scores in training (TCGA) and validation data sets (GSE32894, GSE13507, and GSE48277). The IPS was a useful prognostic factor for patients treated with immunotherapy in the IMvigor210 trial. Hallmarks of multiple oncogenic pathways were significantly enriched in the high risk group. A novel nomogram model was established for prognostic predictions. The dysregulated expression of the selected immune genes between NMIBC and MIBC was also validated in BLCA samples. Conclusion Dysregulation of the immune microenvironment promoted the malignant progression from NMIBC to MIBC. The IPS can stratify patients into different risk groups with distinct prognoses and immunotherapeutic susceptibility, thus facilitating personalized immunotherapy.

High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study

[Association of Bmi-1 Expression with Clinicopathological Features and Prognosis of Colorectal Cancer].

Identification of Spindle and Kinetochore-Associated Family Genes As Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment

B7-H4 is A Prognostic Biomarker for Poor Survival in Patients with Pancreatic Cancer

Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

[Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas]

Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases.

Prognostic Implications of MYBL2 in Resected Chinese Gastric Adenocarcinoma Patients

Potential Roles of PBRM1 on Immune Infiltration in Cholangiocarcinoma.

BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers

The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and <i>in vitro</i> validation

Bmi-1 Promotes the Chemoresistance, Invasion and Tumorigenesis of Pancreatic Cancer Cells

BRM/SMARCA2 Promotes the Proliferation and Chemoresistance of Pancreatic Cancer Cells by Targeting JAK2/STAT3 Signaling

Overexpression of KLF5 is Associated with Poor Survival and G1/S Progression in Pancreatic Cancer

Polycomb Group Protein Bmi1 Expression in Colon Cancers Predicts the Survival.

Comprehensive Analyses of PBRM1 in Multiple Cancer Types and Its Association with Clinical Response to Immunotherapy and Immune Infiltrates.

BOP1 Used as a Novel Prognostic Marker and Correlated with Tumor Microenvironment in Pan-Cancer

Discovery of a Novel Bloom's Syndrome Protein (BLM) Inhibitor Suppressing Growth and Metastasis of Prostate Cancer

The Distribution and Expression of the Bloom’s Syndrome Gene Product in Normal and Neoplastic Human Cells

Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer

BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma